Price to Earnings (P/E)
since 2005
Calculation
Vertex Pharmaceuticals Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss)1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | 31.58 | = | 491.47 | ÷ | 15.56 | 15.56 | = | 3,953,200 | ÷ | 254,034,190 | |
| Feb 13, 2025 | — | = | 462.58 | ÷ | -2.09 | -2.09 | = | -535,600 | ÷ | 256,789,869 | |
| Feb 15, 2024 | 30.42 | = | 426.29 | ÷ | 14.01 | 14.01 | = | 3,619,600 | ÷ | 258,307,816 | |
| Feb 10, 2023 | 23.02 | = | 297.40 | ÷ | 12.92 | 12.92 | = | 3,322,000 | ÷ | 257,091,441 | |
| Feb 9, 2022 | 26.55 | = | 244.24 | ÷ | 9.20 | 9.20 | = | 2,342,100 | ÷ | 254,576,691 | |
| Feb 11, 2021 | 20.18 | = | 210.50 | ÷ | 10.43 | 10.43 | = | 2,711,647 | ÷ | 259,960,062 | |
| Feb 13, 2020 | 52.90 | = | 240.09 | ÷ | 4.54 | 4.54 | = | 1,176,810 | ÷ | 259,268,593 | |
| Feb 13, 2019 | 22.59 | = | 185.25 | ÷ | 8.20 | 8.20 | = | 2,096,896 | ÷ | 255,656,889 | |
| Feb 15, 2018 | 155.08 | = | 160.94 | ÷ | 1.04 | 1.04 | = | 263,484 | ÷ | 253,891,984 | |
| Feb 23, 2017 | — | = | 85.73 | ÷ | -0.45 | -0.45 | = | -112,052 | ÷ | 248,438,127 | |
| Feb 16, 2016 | — | = | 85.37 | ÷ | -2.26 | -2.26 | = | -556,334 | ÷ | 246,391,955 | |
| Feb 13, 2015 | — | = | 113.66 | ÷ | -3.05 | -3.05 | = | -738,555 | ÷ | 242,088,884 | |
| Feb 11, 2014 | — | = | 84.98 | ÷ | -1.89 | -1.89 | = | -445,028 | ÷ | 235,771,942 | |
| Mar 1, 2013 | — | = | 46.17 | ÷ | -0.49 | -0.49 | = | -107,032 | ÷ | 218,188,628 | |
| Feb 22, 2012 | 267.42 | = | 37.60 | ÷ | 0.14 | 0.14 | = | 29,574 | ÷ | 210,335,993 | |
| Feb 17, 2011 | — | = | 39.85 | ÷ | -3.69 | -3.69 | = | -754,626 | ÷ | 204,412,712 | |
| Feb 19, 2010 | — | = | 40.70 | ÷ | -3.20 | -3.20 | = | -642,178 | ÷ | 200,576,408 | |
| Feb 17, 2009 | — | = | 33.10 | ÷ | -3.02 | -3.02 | = | -459,851 | ÷ | 152,189,782 | |
| Feb 11, 2008 | — | = | 18.21 | ÷ | -2.94 | -2.94 | = | -391,279 | ÷ | 132,964,533 | |
| Mar 1, 2007 | — | = | 30.03 | ÷ | -1.63 | -1.63 | = | -206,891 | ÷ | 126,650,456 | |
| Mar 16, 2006 | — | = | 39.49 | ÷ | -1.85 | -1.85 | = | -203,417 | ÷ | 109,734,852 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Vertex Pharmaceuticals Inc. Annual Report.
The price-to-earnings (P/E) ratio exhibits significant fluctuations over the observed period. Initially, the ratio is unavailable for several years, reflecting periods of negative earnings per share (EPS). A substantial P/E ratio of 267.42 is recorded in 2012, coinciding with a small positive EPS value following years of losses. Subsequently, the P/E ratio experiences considerable volatility, ranging from a high of 155.08 in 2017 to a low of 20.18 in 2021.
- Early Period (2006-2011)
- The P/E ratio is not calculable for the initial years due to consistently negative EPS. This indicates the company was not generating profits during this timeframe, making the P/E ratio meaningless as an investment metric.
- Transition and Volatility (2012-2017)
- The emergence of a positive, albeit small, EPS in 2012 results in a very high P/E ratio. This suggests the market had high expectations for future earnings growth. The P/E ratio then declines significantly to 155.08 in 2017, indicating increasing earnings and potentially a more rational market valuation. This period demonstrates considerable volatility, likely influenced by developments in the company’s pipeline and clinical trial results.
- Stabilization and Recent Trends (2018-2024)
- From 2018 onwards, the P/E ratio generally stabilizes, though fluctuations persist. The ratio decreases substantially in 2018 and 2019 as EPS increases dramatically. A subsequent rise in 2020 is followed by a decrease in 2021. In 2023, the P/E ratio is 30.42. The most recent available value, for 2024, shows a negative EPS and therefore an uncalculable P/E ratio.
Overall, the P/E ratio demonstrates a strong correlation with EPS. Periods of negative EPS result in an undefined P/E ratio, while increases in EPS generally lead to a decrease in the P/E ratio, and vice versa. The observed volatility suggests the market’s valuation of the company is sensitive to changes in earnings performance.
AI Ask an analyst for more
Comparison to Competitors
Vertex Pharmaceuticals Inc., P/E, long-term trends, comparison to competitors
| Vertex Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | 31.58 | 94.06 | 25.81 | 17.30 | 40.93 | 47.45 | 21.54 | 21.66 | 16.79 | 19.83 | 18.19 | 28.82 |
| Feb 13, 2025 | — | 79.59 | 38.24 | — | 38.12 | 77.63 | 296.57 | 26.92 | 13.49 | 18.42 | 17.76 | 32.03 |
| Feb 15, 2024 | 30.42 | 63.84 | 23.14 | 12.27 | 39.09 | 135.24 | 16.17 | 10.73 | 893.99 | 73.42 | 25.99 | 35.65 |
| Feb 10, 2023 | 23.02 | 22.62 | 19.56 | 23.97 | 25.65 | 50.08 | 22.68 | 22.97 | 19.21 | 7.58 | 19.68 | 30.55 |
| Feb 9, 2022 | 26.55 | 22.07 | 21.05 | 20.92 | 29.94 | 40.66 | 12.36 | 20.93 | 14.78 | 11.76 | 8.37 | 27.35 |
| Feb 11, 2021 | 20.18 | 40.17 | 18.82 | — | 44.49 | 31.95 | 641.48 | 28.92 | 26.72 | 19.62 | 15.09 | 27.89 |
| Feb 13, 2020 | 52.90 | 17.82 | 17.07 | 41.99 | 38.34 | 16.19 | 16.45 | 25.99 | 20.60 | 11.63 | 19.86 | 33.36 |
| Feb 13, 2019 | 22.59 | 20.60 | 14.01 | 16.81 | 29.77 | 39.13 | 15.26 | 23.74 | 33.46 | 21.58 | 18.17 | 35.19 |
| Feb 15, 2018 | 155.08 | 35.47 | 64.06 | 103.55 | 27.25 | — | 22.75 | 268.10 | 61.63 | 9.99 | 28.99 | 37.66 |
| Feb 23, 2017 | — | 16.54 | 16.03 | 20.56 | 23.02 | 32.39 | 6.83 | 20.08 | 46.14 | 28.10 | 42.64 | 30.45 |
| Feb 16, 2016 | — | 17.01 | 15.95 | 64.22 | 17.85 | 33.35 | 6.75 | 18.80 | 31.64 | 26.37 | 60.50 | 26.19 |
| Feb 13, 2015 | — | 55.08 | 22.96 | 49.80 | 23.69 | 33.06 | 12.85 | 17.15 | 13.94 | 23.03 | 118.44 | 27.26 |
| Feb 11, 2014 | — | 19.64 | 18.69 | 35.01 | 19.74 | 13.88 | 42.00 | 18.72 | 37.83 | 9.32 | 77.00 | 38.43 |
| Mar 1, 2013 | — | 11.51 | 15.68 | 30.56 | 17.73 | 14.99 | 25.20 | 19.64 | 20.94 | 13.51 | 21.42 | 22.54 |
| Feb 22, 2012 | 267.42 | — | 14.61 | 15.07 | 16.92 | 10.42 | 12.20 | 18.48 | 18.63 | 15.99 | — | 15.58 |
| Feb 17, 2011 | — | — | 10.53 | 13.99 | 18.29 | 7.86 | 10.68 | 12.23 | 116.63 | 18.63 | — | 20.87 |
| Feb 19, 2010 | — | — | 12.10 | 4.03 | 20.93 | 9.18 | 16.29 | 14.22 | 9.00 | 16.41 | — | 23.49 |
| Feb 17, 2009 | — | — | 12.06 | 7.68 | 12.56 | — | 20.29 | 11.67 | 6.53 | 10.25 | — | 15.25 |
| Feb 11, 2008 | — | — | 15.64 | 20.60 | 17.35 | 19.26 | 25.19 | 17.07 | 29.88 | 18.51 | — | 30.76 |
| Mar 1, 2007 | — | — | 25.43 | 34.64 | 19.65 | 22.40 | — | 17.02 | 21.57 | 9.18 | — | 113.28 |
| Mar 16, 2006 | — | — | 23.70 | 14.96 | 21.38 | 31.90 | 34.15 | 16.95 | 16.62 | 23.92 | — | 25.36 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Vertex Pharmaceuticals Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 13, 2026 | 31.58 | 28.98 |
| Feb 13, 2025 | — | 45.15 |
| Feb 15, 2024 | 30.42 | 32.80 |
| Feb 10, 2023 | 23.02 | 20.23 |
| Feb 9, 2022 | 26.55 | 19.27 |
| Feb 11, 2021 | 20.18 | 34.89 |
| Feb 13, 2020 | 52.90 | 21.03 |
| Feb 13, 2019 | 22.59 | 22.89 |
| Feb 15, 2018 | 155.08 | 35.21 |
| Feb 23, 2017 | — | 20.62 |
| Feb 16, 2016 | — | 19.37 |
| Feb 13, 2015 | — | 21.40 |
| Feb 11, 2014 | — | 19.54 |
| Mar 1, 2013 | — | 17.56 |
| Feb 22, 2012 | 267.42 | 16.42 |
| Feb 17, 2011 | — | 16.11 |
| Feb 19, 2010 | — | 11.66 |
| Feb 17, 2009 | — | 12.21 |
| Feb 11, 2008 | — | 20.04 |
| Mar 1, 2007 | — | 17.46 |
| Mar 16, 2006 | — | 20.94 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Vertex Pharmaceuticals Inc., P/E, long-term trends, comparison to industry (health care)
| Vertex Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 13, 2026 | 31.58 | 28.31 |
| Feb 13, 2025 | — | 38.03 |
| Feb 15, 2024 | 30.42 | 30.62 |
| Feb 10, 2023 | 23.02 | 351,256.81 |
| Feb 9, 2022 | 26.55 | 21.55 |
| Feb 11, 2021 | 20.18 | 32.22 |
| Feb 13, 2020 | 52.90 | 22.09 |
| Feb 13, 2019 | 22.59 | 24.32 |
| Feb 15, 2018 | 155.08 | 33.04 |
| Feb 23, 2017 | — | 21.90 |
| Feb 16, 2016 | — | 19.53 |
| Feb 13, 2015 | — | 21.38 |
| Feb 11, 2014 | — | 18.67 |
| Mar 1, 2013 | — | 15.77 |
| Feb 22, 2012 | 267.42 | 15.79 |
| Feb 17, 2011 | — | 15.12 |
| Feb 19, 2010 | — | 11.71 |
| Feb 17, 2009 | — | 13.07 |
| Feb 11, 2008 | — | 19.29 |
| Mar 1, 2007 | — | 18.61 |
| Mar 16, 2006 | — | 21.71 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).